In summary, depending on differences in the microenvironment and the additional genetic background, our data are the first - to the best of our knowledge - to conclusively suggest that low Cdh1 expression may be important in AML biology by contributing to the differentiation block in non-APL AML and response to therapy in APL. This evidence concerns the gene CDH1 and acute promyelocytic leukemia.